New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
09:07 EDTOXGNOxigene presents encouraging OXi4503 preclinical and clinical data
Oxigene announced that investigators at the University of Florida presented encouraging clinical data using Oxigene's vascular disrupting agent, or VDA, OXi4503, in patients with acute myelogenous leukemia, or AML, at the annual meeting of the American Society of Hematology in Atlanta, Georgia. The data showed responses and a manageable safety profile in this first-in-man trial of a VDA in AML. Overall response was 2/5, or 40%, with 1 patient achieving a marrow complete remission, or mCR, and 1 patient achieving a partial remission. The median number of cycles was 1, in a range of 1-6. Three of 5 subjects discontinued the study due to AML progression and one due to pneumonia. One patient with AML treated with 5 mg/m2 OXi4503 has received 6 months of treatment and continues to receive weekly infusions.
News For OXGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
16:05 EDTOXGNOXiGENE announces issuance of European patent for OXi4503
Subscribe for More Information
November 12, 2014
16:02 EDTOXGNOXiGENE reports Q3 EPS (17c), consensus (23c)
Subscribe for More Information
November 10, 2014
05:44 EDTOXGNOXiGENE reports Phase 2 GOG 186I study achieves primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use